DIEBOLD NIXDORF INC (DBD) Fundamental Analysis & Valuation

NYSE:DBD • US2536512021

Current stock price

71.7 USD
+0.21 (+0.29%)
At close:
71.7 USD
0 (0%)
After Hours:

This DBD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. DBD Profitability Analysis

1.1 Basic Checks

  • DBD had positive earnings in the past year.
  • In the past year DBD had a positive cash flow from operations.
  • In multiple years DBD reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: DBD reported negative operating cash flow in multiple years.
DBD Yearly Net Income VS EBIT VS OCF VS FCFDBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B

1.2 Ratios

  • DBD has a better Return On Assets (2.45%) than 67.57% of its industry peers.
  • DBD has a Return On Equity of 8.60%. This is in the better half of the industry: DBD outperforms 78.38% of its industry peers.
  • With a decent Return On Invested Capital value of 10.65%, DBD is doing good in the industry, outperforming 75.68% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for DBD is significantly below the industry average of 15.90%.
  • The last Return On Invested Capital (10.65%) for DBD is above the 3 year average (8.32%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 2.45%
ROE 8.6%
ROIC 10.65%
ROA(3y)11.68%
ROA(5y)2.77%
ROE(3y)45.39%
ROE(5y)N/A
ROIC(3y)8.32%
ROIC(5y)6.73%
DBD Yearly ROA, ROE, ROICDBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 200 300

1.3 Margins

  • With a decent Profit Margin value of 2.49%, DBD is doing good in the industry, outperforming 67.57% of the companies in the same industry.
  • The Operating Margin of DBD (8.79%) is better than 78.38% of its industry peers.
  • DBD's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 26.37%, DBD is in line with its industry, outperforming 45.95% of the companies in the same industry.
  • DBD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 8.79%
PM (TTM) 2.49%
GM 26.37%
OM growth 3Y151.18%
OM growth 5Y22.46%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.45%
GM growth 5Y-0.54%
DBD Yearly Profit, Operating, Gross MarginsDBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. DBD Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so DBD is still creating some value.
  • The number of shares outstanding for DBD has been reduced compared to 1 year ago.
  • The number of shares outstanding for DBD has been reduced compared to 5 years ago.
  • DBD has a better debt/assets ratio than last year.
DBD Yearly Shares OutstandingDBD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
DBD Yearly Total Debt VS Total AssetsDBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

  • An Altman-Z score of 1.98 indicates that DBD is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 1.98, DBD is in line with its industry, outperforming 56.76% of the companies in the same industry.
  • DBD has a debt to FCF ratio of 3.59. This is a good value and a sign of high solvency as DBD would need 3.59 years to pay back of all of its debts.
  • DBD's Debt to FCF ratio of 3.59 is fine compared to the rest of the industry. DBD outperforms 67.57% of its industry peers.
  • A Debt/Equity ratio of 0.85 indicates that DBD is somewhat dependend on debt financing.
  • DBD has a Debt to Equity ratio (0.85) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF 3.59
Altman-Z 1.98
ROIC/WACC1.36
WACC7.82%
DBD Yearly LT Debt VS Equity VS FCFDBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B -1B 2B

2.3 Liquidity

  • DBD has a Current Ratio of 1.30. This is a normal value and indicates that DBD is financially healthy and should not expect problems in meeting its short term obligations.
  • DBD's Current ratio of 1.30 is in line compared to the rest of the industry. DBD outperforms 43.24% of its industry peers.
  • A Quick Ratio of 0.92 indicates that DBD may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.92, DBD perfoms like the industry average, outperforming 45.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 0.92
DBD Yearly Current Assets VS Current LiabilitesDBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. DBD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 40.93% over the past year.
  • Measured over the past years, DBD shows a very strong growth in Earnings Per Share. The EPS has been growing by 48.24% on average per year.
  • DBD shows a small growth in Revenue. In the last year, the Revenue has grown by 1.46%.
  • DBD shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.50% yearly.
EPS 1Y (TTM)40.93%
EPS 3YN/A
EPS 5Y48.24%
EPS Q2Q%183.51%
Revenue 1Y (TTM)1.46%
Revenue growth 3Y3.22%
Revenue growth 5Y-0.5%
Sales Q2Q%11.66%

3.2 Future

  • DBD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.66% yearly.
  • DBD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.76% yearly.
EPS Next Y1.85%
EPS Next 2Y11.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.28%
Revenue Next 2Y2.76%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DBD Yearly Revenue VS EstimatesDBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B 4B
DBD Yearly EPS VS EstimatesDBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

5

4. DBD Valuation Analysis

4.1 Price/Earnings Ratio

  • DBD is valuated correctly with a Price/Earnings ratio of 13.18.
  • Based on the Price/Earnings ratio, DBD is valued cheaper than 89.19% of the companies in the same industry.
  • DBD's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.73.
  • A Price/Forward Earnings ratio of 12.94 indicates a correct valuation of DBD.
  • Based on the Price/Forward Earnings ratio, DBD is valued a bit cheaper than 70.27% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of DBD to the average of the S&P500 Index (23.72), we can say DBD is valued slightly cheaper.
Industry RankSector Rank
PE 13.18
Fwd PE 12.94
DBD Price Earnings VS Forward Price EarningsDBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, DBD is valued cheaply inside the industry as 94.59% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, DBD is valued cheaper than 81.08% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.58
EV/EBITDA 6.56
DBD Per share dataDBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DBD does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)7.13
PEG (5Y)0.27
EPS Next 2Y11.66%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DBD Dividend Analysis

5.1 Amount

  • DBD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DBD Fundamentals: All Metrics, Ratios and Statistics

DIEBOLD NIXDORF INC

NYSE:DBD (3/19/2026, 8:04:00 PM)

After market: 71.7 0 (0%)

71.7

+0.21 (+0.29%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)02-12
Earnings (Next)05-05
Inst Owners104.32%
Inst Owner Change-2.29%
Ins Owners1.83%
Ins Owner Change0.97%
Market Cap2.52B
Revenue(TTM)3.81B
Net Income(TTM)94.60M
Analysts82.86
Price Target98.6 (37.52%)
Short Float %2.51%
Short Ratio3.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)57.23%
Min EPS beat(2)46.39%
Max EPS beat(2)68.07%
EPS beat(4)4
Avg EPS beat(4)43.94%
Min EPS beat(4)1.76%
Max EPS beat(4)68.07%
EPS beat(8)6
Avg EPS beat(8)66.37%
EPS beat(12)8
Avg EPS beat(12)-75.33%
EPS beat(16)10
Avg EPS beat(16)-76.24%
Revenue beat(2)0
Avg Revenue beat(2)-1.02%
Min Revenue beat(2)-1.85%
Max Revenue beat(2)-0.2%
Revenue beat(4)1
Avg Revenue beat(4)-0.09%
Min Revenue beat(4)-1.85%
Max Revenue beat(4)3.02%
Revenue beat(8)3
Avg Revenue beat(8)0.08%
Revenue beat(12)4
Avg Revenue beat(12)-0.54%
Revenue beat(16)4
Avg Revenue beat(16)-1.85%
PT rev (1m)22.36%
PT rev (3m)22.36%
EPS NQ rev (1m)-5.6%
EPS NQ rev (3m)-5.6%
EPS NY rev (1m)12.72%
EPS NY rev (3m)12.72%
Revenue NQ rev (1m)-2.07%
Revenue NQ rev (3m)-2.07%
Revenue NY rev (1m)0.13%
Revenue NY rev (3m)0.13%
Valuation
Industry RankSector Rank
PE 13.18
Fwd PE 12.94
P/S 0.66
P/FCF 9.58
P/OCF 8.39
P/B 2.29
P/tB N/A
EV/EBITDA 6.56
EPS(TTM)5.44
EY7.59%
EPS(NY)5.54
Fwd EY7.73%
FCF(TTM)7.49
FCFY10.44%
OCF(TTM)8.55
OCFY11.92%
SpS108.21
BVpS31.27
TBVpS-9.52
PEG (NY)7.13
PEG (5Y)0.27
Graham Number61.87
Profitability
Industry RankSector Rank
ROA 2.45%
ROE 8.6%
ROCE 13.48%
ROIC 10.65%
ROICexc 12.68%
ROICexgc 40.66%
OM 8.79%
PM (TTM) 2.49%
GM 26.37%
FCFM 6.92%
ROA(3y)11.68%
ROA(5y)2.77%
ROE(3y)45.39%
ROE(5y)N/A
ROIC(3y)8.32%
ROIC(5y)6.73%
ROICexc(3y)9.91%
ROICexc(5y)8.22%
ROICexgc(3y)32.13%
ROICexgc(5y)32.22%
ROCE(3y)10.53%
ROCE(5y)8.51%
ROICexgc growth 3Y61.28%
ROICexgc growth 5Y10.41%
ROICexc growth 3Y110.53%
ROICexc growth 5Y16.22%
OM growth 3Y151.18%
OM growth 5Y22.46%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.45%
GM growth 5Y-0.54%
F-Score7
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF 3.59
Debt/EBITDA 2.03
Cap/Depr 29.33%
Cap/Sales 0.98%
Interest Coverage 5.66
Cash Conversion 65.07%
Profit Quality 278.33%
Current Ratio 1.3
Quick Ratio 0.92
Altman-Z 1.98
F-Score7
WACC7.82%
ROIC/WACC1.36
Cap/Depr(3y)20.25%
Cap/Depr(5y)18.73%
Cap/Sales(3y)0.7%
Cap/Sales(5y)0.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.93%
EPS 3YN/A
EPS 5Y48.24%
EPS Q2Q%183.51%
EPS Next Y1.85%
EPS Next 2Y11.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.46%
Revenue growth 3Y3.22%
Revenue growth 5Y-0.5%
Sales Q2Q%11.66%
Revenue Next Year2.28%
Revenue Next 2Y2.76%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.5%
EBIT growth 3Y159.26%
EBIT growth 5Y21.84%
EBIT Next Year56.52%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y99.77%
FCF growth 3YN/A
FCF growth 5Y25.37%
OCF growth 1Y101.54%
OCF growth 3YN/A
OCF growth 5Y21.73%

DIEBOLD NIXDORF INC / DBD Fundamental Analysis FAQ

What is the fundamental rating for DBD stock?

ChartMill assigns a fundamental rating of 5 / 10 to DBD.


Can you provide the valuation status for DIEBOLD NIXDORF INC?

ChartMill assigns a valuation rating of 5 / 10 to DIEBOLD NIXDORF INC (DBD). This can be considered as Fairly Valued.


What is the profitability of DBD stock?

DIEBOLD NIXDORF INC (DBD) has a profitability rating of 5 / 10.


What is the financial health of DIEBOLD NIXDORF INC (DBD) stock?

The financial health rating of DIEBOLD NIXDORF INC (DBD) is 5 / 10.


How sustainable is the dividend of DIEBOLD NIXDORF INC (DBD) stock?

The dividend rating of DIEBOLD NIXDORF INC (DBD) is 0 / 10 and the dividend payout ratio is 0%.